Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1828-1834

  Solomon, Scott R ^a   Sanacore, Melissa ^a   Zhang, Xu ^b   Brown, Stacey ^a   Holland, Kent ^a   Morris, Lawrence E ^a   Bashey, Asad ^a  

^a NORTHSIDE HOSPITAL   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Allogeneic; Graft versus host disease; Peripheral blood stem cell transplantation; Post transplantation cyclophosphamide; Reduced intensity conditioning; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHATIC LEUKEMIA; MALE; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; SURVIVAL TIME; ADVERSE EFFECTS; CLINICAL TRIAL; DONOR; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROSPECTIVE STUDY;

ADULT; AGED; CALCINEURIN INHIBITORS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; SIROLIMUS; TISSUE DONORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 84908046608     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.020     Document Type: Article

References (71)

1. Appelbaum F.R., Forman S.J., Negrin R.S., Blume K.G. Thomas' hematopoietic cell transplantation 2004, Wiley, New York. 4th ed.
2. Gale R.P., Champlin R.E. How does bone-marrow transplantation cure leukaemia?. Lancet 1984, 324:28-30.
3. Champlin R., Khouri I., Shimoni A., et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000, 111:18-29.
4. Shimoni A., Nagler A. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. Curr Hematol Rep 2004, 3:242-248.
5. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
6. Bertz H., Illerhaus G., Veelken H., Finke J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002, 13:135-139.
7. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
8. Chao N.J., Snyder D.S., Jain M., et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000, 6:254-261.
9. Locatelli F., Bruno B., Zecca M., et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft-versus-host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000, 96:1690-1697.
10. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
11. Pavletic S.Z., Carter S.L., Kernan N.A., et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005, 106:3308-3313.
12. Uberti J.P., Ayash L., Braun T., et al. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Bone Marrow Transplant 2004, 34:425-431.
13. Flowers M.E., Parker P.M., Johnston L.J., et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002, 100:415-419.
14. Mohty M., Kuentz M., Michallet M., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 2002, 100:3128-3134.
15. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
16. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
17. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. JClin Invest 2003, 112:1688-1696.
18. + regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008, 112:2129-2138.
19. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
20. + regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006, 107:1717-1723.
21. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005, 106:2903-2911.
22. + T cells. Bone Marrow Transplant 2007, 39:537-545.
23. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.
24. Kanakry C.G., Ganguly S., Zahurak M., et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013, 5:ra157.
25. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
26. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005, 11:945-956.
27. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 84:360-372.
28. Klein J.P., Rizzo J.D., Zhang M.J., Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants, part 2: regression modeling. Bone Marrow Transplant 2001, 28:1001-1011.
29. Gray R.J. Aclass of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
30. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. JClin Oncol 2013, 31:1310-1316.
31. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced-intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
32. Luznik L., Bolanos-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115:3224-3230.
33. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
34. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386.
35. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell-replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
36. Luznik L., Engstrom L.W., Iannone R., Fuchs E.J. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002, 8:131-138.
37. Luznik L., Jalla S., Engstrom L.W., et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001, 98:3456-3464.
38. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340.
39. + regulatory T cells. Blood 2005, 105:4743-4748.
40. Hackstein H., Taner T., Logar A.J., Thomson A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002, 100:1084-1087.
41. Hackstein H., Taner T., Zahorchak A.F., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation invitro and dendritic cell mobilization and function invivo. Blood 2003, 101:4457-4463.
42. Monti P., Mercalli A., Leone B.E., et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003, 75:137-145.
43. Jain S., Bicknell G.R., Whiting P.H., Nicholson M.L. Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc 2001, 33:556-558.
44. Zhu J., Wu J., Frizell E., et al. Rapamycin inhibits hepatic stellate cell proliferation invitro and limits fibrogenesis in an invivo model of liver fibrosis. Gastroenterology 1999, 117:1198-1204.
45. Armand P., Gannamaneni S., Kim H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. JClin Oncol 2008, 26:5767-5774.
46. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
47. Sillaber C., Mayerhofer M., Bohm A., et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008, 38:43-52.
48. Majewski M., Korecka M., Kossev P., et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes invitro and invivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000, 97:4285-4290.
49. Marty F.M., Bryar J., Browne S.K., et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007, 110:490-500.
50. Fitzhugh C.D., Weitzel R.P., Hsieh M.M., et al. Sirolimus and post-transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplant 2013, 48:1335-1341.
51. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112:4425-4431.
52. Johnston L., Florek M., Armstrong R., et al. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant 2012, 47:581-588.
53. Kiel P.J., Vargo C.A., Patel G.P., et al. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation. Pharmacotherapy 2012, 32:441-445.
54. Rosenbeck L.L., Kiel P.J., Kalsekar I., et al. Prophylaxis with sirolimus and tacrolimus+/- antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:916-922.
55. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. NEngl J Med 2012, 367:1487-1496.
56. Ringden O., Remberger M., Runde V., et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999, 94:455-464.
57. Vigorito A.C., Azevedo W.M., Marques J.F., et al. Arandomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998, 22:1145-1151.
58. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004, 104:3501-3506.
59. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
60. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. JClin Oncol 2006, 24:444-453.
61. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
62. Sureda A., Canals C., Arranz R., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with relapsed or refractory Hodgkin lymphoma: results of the HDR-ALLO study, a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012, 97:310-317.
63. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. JClin Oncol 2008, 26:577-584.
64. Haritunians T., Mori A., O'Kelly J., et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2006, 21:333-339.
65. Decker T., Hipp S., Ringshausen I., et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003, 101:278-285.
66. Jundt F., Raetzel N., Müller C., et al. Arapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005, 106:1801-1807.
67. Wanner K., Hipp S., Oelsner M., et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006, 134:475-484.
68. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. JClin Oncol 2009, 27:3822-3829.
69. Renner C., Zinzani P.L., Gressin R., et al. Amulticenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012, 97:1085-1091.
70. Smith S.M., van Besien K., Karrison T., et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago Phase II Consortium. JClin Oncol 2010, 28:4740-4746.
71. Witzig T.E., Reeder C.B., LaPlant B.R., et al. Aphase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25:341-347.